| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
(1S,4S)-N-Desmethyl Sertraline targets the serotonin transporter (SERT, SLC6A4) as a selective serotonin uptake blocker. It inhibits the reuptake of serotonin from the synaptic cleft into the presynaptic neuron, thereby increasing serotonin availability at serotonergic synapses. However, this metabolite is significantly less active than the parent compound sertraline in inhibiting serotonin reuptake. It is primarily used as an analytical standard for studying sertraline metabolism and pharmacokinetics.
|
|---|---|
| ln Vitro |
In vitro, (1S,4S)-N-Desmethyl Sertraline acts as a selective serotonin uptake inhibitor, though with significantly reduced potency compared to the parent compound sertraline. No specific IC50 values for serotonin uptake inhibition are reported in the search results. The metabolite is used primarily as an analytical reference standard rather than a pharmacological tool. The compound does not possess significant intrinsic antidepressant activity in vivo due to its lower potency and is considered a pharmacologically inactive or weakly active metabolite.
|
| ln Vivo |
No in vivo activity data are specifically reported for (1S,4S)-N-Desmethyl Sertraline hydrochloride itself. As a metabolite of sertraline, it is formed in vivo after sertraline administration. The compound has no direct therapeutic use and is not administered as a drug. It is used in pharmacokinetic studies to quantify sertraline metabolism and to assess the role of CYP450 enzymes (primarily CYP2B6, CYP2C19, and CYP3A4) in sertraline demethylation.
|
| Enzyme Assay |
Binding of (1S,4S)-N-Desmethyl Sertraline to the serotonin transporter (SERT) is measured by competitive binding assays using membrane preparations from cells expressing human SERT. The compound is incubated with [3H]paroxetine or [3H]citalopram (radioligands for SERT) in Tris-HCl buffer. Nonspecific binding is determined using 10 microM fluoxetine or sertraline. The radioactivity is counted, and Ki or IC50 is calculated. No specific Ki value is reported. The compound is typically characterized by HPLC, LC-MS/MS, and NMR for identity and purity.
|
| Cell Assay |
No cellular assays for serotonin uptake inhibition are specifically described for this metabolite. In a typical assay, HEK293 cells expressing human SERT or rat brain synaptosomes are incubated with [3H]serotonin and the test compound at graded concentrations. After incubation, the reaction is terminated, and radioactivity in the lysate is counted. The IC50 is calculated from the inhibition of [3H]serotonin uptake. This metabolite is expected to show significantly higher IC50 (lower potency) compared to sertraline (IC50 for sertraline ~3-10 nM).
|
| Animal Protocol |
No animal experiments are performed directly on (1S,4S)-N-Desmethyl Sertraline hydrochloride. In pharmacokinetic studies, sertraline is administered to rats or mice (oral or IV, 1-10 mg/kg), and blood and brain samples are collected at various time points. The metabolite is quantified in these samples by LC-MS/MS to assess the rate and extent of N-demethylation. The ratio of parent drug to metabolite in plasma and brain is calculated. No in vivo efficacy studies (e.g., forced swim test) are performed using the metabolite alone.
|
| ADME/Pharmacokinetics |
(1S,4S)-N-Desmethyl Sertraline hydrochloride (C1₆H1₆Cl3N, MW = 328.66, exact mass = 327.0354) is a red-orange solid. It is soluble in DMSO, methanol, and ethanol. For analytical use, stock solutions (1 mg/mL) are prepared in methanol or acetonitrile and stored at -20degC. For LC-MS/MS analysis, calibration curves are prepared in blank plasma or brain homogenate. The compound is stable at -20degC for extended periods. No in vivo PK data for the metabolite alone are applicable as it is not administered directly. The half-life of the metabolite in humans following sertraline administration is approximately 2-3 days (longer than sertraline due to slower clearance).
|
| Toxicity/Toxicokinetics |
No toxicity data are reported specifically for (1S,4S)-N-Desmethyl Sertraline hydrochloride. As a metabolite of sertraline, it contributes to the overall safety profile of sertraline but is not considered toxic at concentrations achieved during therapy. The compound is for research use only as an analytical standard and is not intended for human consumption. Standard laboratory safety precautions should be followed when handling the compound. No formal toxicological studies have been conducted on this metabolite alone.
|
| References | |
| Additional Infomation |
(1S,4S)-N-Desmethyl Sertraline hydrochloride is the N-demethylated metabolite of the selective serotonin reuptake inhibitor (SSRI) sertraline (Zoloft). Sertraline is one of the most widely prescribed antidepressants worldwide. This metabolite is formed primarily by CYP2B6, CYP2C19, and CYP3A4 enzymes and is significantly less pharmacologically active than the parent compound. It is used as an analytical reference standard in pharmaceutical research, clinical toxicology, and therapeutic drug monitoring to quantify sertraline metabolism and assess patient compliance. The compound is for research use only and has no therapeutic applications. It has not received regulatory approval as a drug. The (1S,4S) stereoisomer refers to the active cis-configuration of the naphthylamine ring system, which is the same stereochemistry as the parent drug sertraline. CAS 675126-10-0 is the specific identifier for this enantiomerically pure metabolite hydrochloride salt.
|
| Molecular Formula |
C16H16CL3N
|
|---|---|
| Molecular Weight |
328.66
|
| Exact Mass |
327.035
|
| CAS # |
675126-10-0
|
| PubChem CID |
25008634
|
| Appearance |
Typically exists as solid at room temperature
|
| Melting Point |
301-303ºC
|
| LogP |
6.421
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
20
|
| Complexity |
309
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@@H](C2=CC=CC=C2[C@@H]1C3=CC(=C(C=C3)Cl)Cl)N.Cl
|
| InChi Key |
YKXHIERZIRLOLD-RISSCEEYSA-N
|
| InChi Code |
InChI=1S/C16H15Cl2N.ClH/c17-14-7-5-10(9-15(14)18)11-6-8-16(19)13-4-2-1-3-12(11)13;/h1-5,7,9,11,16H,6,8,19H2;1H/t11-,16-;/m0./s1
|
| Chemical Name |
(1S,4S)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0427 mL | 15.2133 mL | 30.4266 mL | |
| 5 mM | 0.6085 mL | 3.0427 mL | 6.0853 mL | |
| 10 mM | 0.3043 mL | 1.5213 mL | 3.0427 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
